Results 41 to 50 of about 3,281 (174)

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice

Hematology Reports, 2015
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis.
Monica Carpenedo, Silvia Cantoni, Veronica Coccini, Marilena Fedele, Enrica Morra, Enrico Maria Pogliani   +5 more
doaj   +1 more source

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy [PDF]

, 2017
Contains fulltext : 177251.pdf (Publisher’s version ) (Open Access)Romiplostim can improve platelet counts in about 50% of patients with low- or intermediate 1-risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but ...
Hagop Kantarjian, Franklin, J., Kantarjian, H., Becker, Pamela S., Lyons, R.M., Sekeres, M.A., Richard A. Larson, Franklin, Janet, Pamela S. Becker, Larson, Richard A., Mikkael A. Sekeres, Orejudos, Amelia, Janet Franklin, Roger M. Lyons, Sekeres, Mikkael A., Becker, P.S., Fenaux, Pierre, Muus, Petra, Kantarjian, Hagop, Fenaux, P., Amelia Orejudos, Larson, R.A., Pierre Fenaux, Petra Muus, Orejudos, A., Muus, P., Lyons, Roger M.   +26 more
core   +1 more source

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?

Folia Medica Indonesiana, 2016
Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management
Jefri Pratama Susanto
doaj   +1 more source

The role of romiplostim for pediatric patients with immune thrombocytopenia

Therapeutic Advances in Hematology, 2020
The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors used to treat immune thrombocytopenia (ITP) in children and adults.
Hanny Al-Samkari, Rachael F. Grace, David J. Kuter   +2 more
doaj   +1 more source

Discrepant Urinary Findings Between Dipstick Protein and Sulfosalicylic Acid Test in a Patient With Hyaline Casts: A Case Report

Journal of Clinical Laboratory Analysis, EarlyView.
In this post‐transplant patient, increased hyaline casts with negative dipstick protein but positive SSA testing occurred during evolving acute kidney injury and resolved with renal recovery. This discordant urinalysis pattern may warrant confirmatory protein testing and correlation with serial renal function in patients at high risk of AKI.
Yifei Jia, Binquan Chu, Fengjun Chen, Xiangyu Zhu, Chen Hang, Xiaoling Yu, Jinpiao Lin   +6 more
wiley   +1 more source

Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials

, 2020
Background: Treatment for chronic immune thrombocytopenia (cITP) in children is largely limited to immunosuppressive agents. Thrombopoietin receptor agonists (TRAs) have been used to treat cITP in adults for over a decade.
Roy, John, Eisen, Melissa, Donald Beam, Ashok Raj, Alexey Maschan, Jenny Despotovic, Raj, Ashok, John Roy, John Grainger, Despotovic, Jenny, Beam, Donald, Kim, June, Grainger, John, Melissa Eisen, Maschan, Alexey, June Kim, Nichola Cooper, Michael D. Tarantino, Tarantino, Michael D., Cooper, Nichola   +19 more
core   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity

Pharmaceuticals, 2023
Immune thrombocytopenia (ITP) treatment has evolved recently. However, none of the treatments have only benefits without drawbacks. This study aimed to compare the clinical outcomes and adverse drug patterns of Eltrombopag, Romiplostim, Prednisolone ...
Eman Mostafa Hamed, Ahmed R. N. Ibrahim, Mohamed Hussein Meabed, Ahmed M. Khalaf, Doaa Mohamed El Demerdash, Marwa O. Elgendy, Haitham Saeed, Heba F. Salem, Hoda Rabea   +8 more
doaj   +1 more source

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 10, Page 2571-2580, October 2026.
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han, Ning Lin, Jinghang Xu, Sikui Wang, Jinglan Jin, Jia Shang, Yongning Xin, Youwen Tan, Dazhi Zhang, Jinlin Hou, Ping An, Wen Xie, Yujuan Guan, Qingfang Xiong, Hong Wu, Huiguo Ding, Yu Chen, Rongkuan Li, Zhili Wen, Mingqin Lu, Jinhui Yang, Zhongyin Zhou, Yongjian Zhou, Zujiang Yu, Kecan Lin, Wei Wang, Yan Huang, Yuemin Nan, Xinhua Luo, Rongshu Shi, Yi Kang, Tao Han, Shiyan Chen, Kai Wang, Yunfeng Shan, Jiaping Li, Pingguo Liu, Zheng Lu, Jun Chen, Zhen Liu, Liaoyun Zhang, Li Yang, Jifang Sheng, Zhan Zeng, Yanyan Yu, Xiaoyuan Xu   +45 more
wiley   +1 more source